A Phase 1B, Multicenter, Open-Label Study of the Safety and Efficacy of CHS-114 in Combination With Toripalimab With or Without Other Treatments in Participants With Advanced or Metastatic Solid Tumors
Latest Information Update: 08 Nov 2024
At a glance
- Drugs CHS 114 (Primary) ; Toripalimab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Head and neck cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Coherus Biosciences
- 06 Nov 2024 According to Coherus BioSciences Media Release, initial data from this study is expected in the first half of 2026.
- 28 Oct 2024 New trial record